Guilford CEO Search Ends With Appointment Of Bristol Exec
This article was originally published in The Pink Sheet Daily
Bristol VP-Strategy Dean Mitchell will join Guilford Dec. 1, replacing company co-founder Craig Smith, who is retiring. Mitchell is expected to oversee a busy period for the company, which anticipates results from up to 13 late-stage clinical trials during the next 12-18 months.
You may also be interested in...
The supplemental application has a user fee goal date of March 2005. Phase II/III trials of the oral cytotoxic alkylating agent are ongoing for treatment of brain metastases from various cancers.
Co-founder and CEO Craig Smith, MD, will retire in May 2005 unless a successor is found earlier. The company is looking for an executive with “superb credentials in commercial development, financial planning and late-stage product development” who can lead Guilford to profitability, Smith says.
The company expects to meet with FDA shortly to discuss design of a placebo-controlled superiority trial for percutaneous coronary intervention. Aggrastat sales decline beginning to slow; sales could improve in the second half of the year, Guilford says.